Our hypothesis is that local re-introduction of IL-2 into skin bearing cSCC and specifically into the tumor microenvironment will serve to restore both the innate immunity, and effector T-cell function lost through iatrogenic IL-2 suppression thereby re-establishing effective cytotoxic immunity against cSCC. This evidence concerns the gene IL2 and neoplasm.